Characteristic | Data for: | P value | |||
---|---|---|---|---|---|
NSIL group (n = 279) | CIN1 group (n = 233) | CIN2 group (n = 147) | CIN3 group (n = 33) | ||
Age (years) | 35.49 ± 7.00 | 34.24 ± 7.53 | 34.88 ± 6.46 | 35.94 ± 6.86 | 0.202 |
Gravidity | 1.45 ± 1.56 | 1.18 ± 1.31 | 1.39 ± 1.42 | 1.48 ± 1.46 | 0.190 |
Parity | 0.58 ± 0.71 | 0.49 ± 0.63 | 0.63 ± 0.72 | 0.58 ± 0.75 | 0.300 |
Body mass index(kg/m2) | 21.45 ± 3.35 | 21.49 ± 3.23 | 21.14 ± 3.01 | 21.85 ± 3.64 | 0.614 |
Age of first sexual(years) intercourse | 21.77 ± 3.23 | 21.63 ± 3.11 | 21.69 ± 3.17 | 22.18 ± 3.31 | 0.810 |
Sexual age(years) | 13.72 ± 6.85 | 12.61 ± 7.20 | 13.19 ± 6.82 | 13.76 ± 6.58 | 0.333 |
Number of sexual partners | 2.92 ± 2.45 | 3.06 ± 2.32 | 2.96 ± 1.87 | 3.36 ± 2.64 | 0.710 |
Richness indexa | 283.16 ± 214.11 | 301.13 ± 217.65 | 356.93 ± 280.61 | 282.15 ± 239.79 | 0.017 |
CHAO1 indexa | 427.92 ± 301.70 | 465.17 ± 309.90 | 518.29 ± 372.63 | 429.60 ± 332.13 | 0.048 |
ACE indexa | 449.03 ± 308.44 | 488.70 ± 320.63 | 540.30 ± 378.92 | 447.06 ± 343.05 | 0.051 |
Shannon indexa | 1.32 ± 0.62 | 1.40 ± 0.59 | 1.57 ± 0.76 | 1.77 ± 0.84 |  < 0.001 |
Simpson indexa | 0.47 ± 0.20 | 0.50 ± 0.20 | 0.54 ± 0.21 | 0.61 ± 0.21 |  < 0.001 |
Invsimpson indexa | 2.46 ± 2.26 | 2.65 ± 1.81 | 3.20 ± 3.22 | 4.47 ± 5.75 |  < 0.001 |
Native place | Â | Â | Â | Â | 0.890 |
 Beijing | 72 (25.81%) | 62 (26.61%) | 34 (23.13%) | 8 (24.24%) |  |
 Others | 207 (74.19%) | 171 (73.39%) | 113 (76.87%) | 25 (75.76%) |  |
Education | Â | Â | Â | Â | 0.012 |
 Junior high school and below | 21 (7.55%) | 21 (9.01%) | 19 (12.93%) | 6 (18.18%) |  |
 Junior high school to high school | 59 (21.22%) | 45 (19.31%) | 45 (30.61%) | 4 (12.12%) |  |
 Bachelor degree or above | 198 (71.22%) | 167 (71.67%) | 83 (56.46%) | 23 (69.70%) |  |
Family history of cancer | Â | Â | Â | Â | 0.801 |
 No | 189 (67.74%) | 151 (64.81%) | 94 (63.95%) | 23 (69.70%) |  |
 Yes | 90 (32.26%) | 82 (35.19%) | 53 (36.05%) | 10 (30.30%) |  |
History of HPV infection | Â | Â | Â | Â | 0.794 |
 No | 162 (58.06%) | 127 (54.51%) | 79 (53.74%) | 19 (57.58%) |  |
 Yes | 117 (41.94%) | 106 (45.49%) | 68 (46.26%) | 14 (42.42%) |  |
Contraceptive methods | Â | Â | Â | Â | 0.750 |
 Condom | 206 (73.84%) | 176 (75.54%) | 109 (74.15%) | 22 (66.67%) |  |
 Other methods or no contraception | 73 (26.16%) | 57 (24.46%) | 38 (25.85%) | 11 (33.33%) |  |
HPV vaccine | Â | Â | Â | Â | 0.426 |
 Unvaccinated | 200 (71.68%) | 168 (72.10%) | 109 (74.15%) | 28 (84.85%) |  |
 Vaccinated | 79 (28.32%) | 65 (27.90%) | 38 (25.85%) | 5 (15.15%) |  |
Smoking | Â | Â | Â | Â | 0.778 |
 Non-smoking | 252 (90.32%) | 211 (90.56%) | 132 (89.80%) | 28 (84.85%) |  |
 Smoking | 27 (9.68%) | 22 (9.44%) | 15 (10.20%) | 5 (15.15%) |  |
TCT |  |  |  |  |  < 0.001 |
 NSIL | 212 (76.26%) | 129 (55.36%) | 76 (51.70%) | 14 (42.42%) |  |
 ASCUS | 42 (15.11%) | 55 (23.61%) | 35 (23.81%) | 5 (15.15%) |  |
 LSIL | 22 (7.91%) | 46 (19.74%) | 27 (18.37%) | 7 (21.21%) |  |
 ASC-H | 2 (0.72%) | 2 (0.86%) | 4 (2.72%) | 3 (9.09%) |  |
 HSIL | 0 (0.00%) | 1 (0.43%) | 5 (3.40%) | 4 (12.12%) |  |
Transformation zone (TZ) | Â | Â | Â | Â | 0.064 |
 TZ-1 | 206 (73.84%) | 180 (77.25%) | 125 (85.03%) | 27 (81.82%) |  |
 TZ-2 | 36 (12.90%) | 31 (13.30%) | 17 (11.56%) | 3 (9.09%) |  |
 TZ-3 | 37 (13.26%) | 22 (9.44%) | 5 (3.40%) | 3 (9.09%) |  |
Colposcopic impression |  |  |  |  |  < 0.001 |
 No signs of abnormalities | 57 (20.43%) | 45 (19.31%) | 23 (15.65%) | 3 (9.09%) |  |
 LSIL | 199 (71.33%) | 152 (65.24%) | 84 (57.14%) | 4 (12.12%) |  |
 HSIL | 23 (8.24%) | 36 (15.45%) | 40 (27.21%) | 26 (78.79%) |  |